{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:41Z","timestamp":1790717141543,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.anai.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:12:54Z","timestamp":1616803974000},"page":"623-629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor\u2013monoclonal antibodies and desensitization"],"prefix":"10.1016","volume":"126","author":[{"given":"Marina","family":"Labella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.anai.2021.03.008_bib0001","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"6382","key":"10.1016\/j.anai.2021.03.008_bib0002","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.anai.2021.03.008_bib0003","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jaci.2018.02.042","article-title":"Immune checkpoint blockade therapy","volume":"142","author":"Wieder","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2021.03.008_bib0004","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1021\/acs.jproteome.8b00373","article-title":"Quantitative N-terminal footprinting of pathogenic mycobacteria reveals differential protein acetylation","volume":"17","author":"Thompson","year":"2018","journal-title":"J Proteome Res"},{"issue":"1","key":"10.1016\/j.anai.2021.03.008_bib0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Prim"},{"issue":"6","key":"10.1016\/j.anai.2021.03.008_bib0006","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.anai.2021.03.008_bib0007","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaip.2020.08.001","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: introduction","volume":"8","author":"Fleisher","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.anai.2021.03.008_bib0008","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jaip.2020.08.002","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: general concepts","volume":"8","author":"Broyles","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2021.03.008_bib0009","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jaci.2017.06.012","article-title":"Diagnosis and management of anaphylaxis in precision medicine","volume":"140","author":"Castells","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2021.03.008_bib0010","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.anai.2020.04.005","article-title":"Drug hypersensitivity in the fast lane","volume":"124","author":"Jakubovic","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.03.008_bib0011","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.03.008_bib0012","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","article-title":"Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies","volume":"4","author":"Sloane","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2021.03.008_bib0013","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.3389\/fimmu.2019.03010","article-title":"Recalling the biological significance of immune checkpoints on NK cells: a chance to overcome LAG3, PD1, and CTLA4 inhibitory pathways by adoptive NK cell transfer?","volume":"10","author":"Lanuza","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.anai.2021.03.008_bib0014","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/1759-7714.12894","article-title":"Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: a case series","volume":"9","author":"Kanazu","year":"2018","journal-title":"Thorac Cancer"},{"issue":"4","key":"10.1016\/j.anai.2021.03.008_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/CJI.0000000000000076","article-title":"Delayed dermatologic hypersensitivity reaction secondary to ipilimumab","volume":"38","author":"Ludlow","year":"2015","journal-title":"J Immunother"},{"issue":"7","key":"10.1016\/j.anai.2021.03.008_bib0016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/rheumatology\/kez465","article-title":"Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors","volume":"58","author":"Ibraheim","year":"2019","journal-title":"Rheumatology"},{"issue":"17","key":"10.1016\/j.anai.2021.03.008_bib0017","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.anai.2021.03.008_bib0018","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clindermatol.2019.10.015","article-title":"The life-threatening eruptions of immune checkpoint inhibitor therapy","volume":"38","author":"Coleman","year":"2020","journal-title":"Clin Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2021.03.008_bib0019","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1038\/s41424-018-0049-9","article-title":"Immune checkpoint inhibitor-associated colitis and hepatitis","volume":"9","author":"Reddy","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"10.1016\/j.anai.2021.03.008_bib0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.anai.2021.03.008_bib0021","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.anai.2021.03.008_bib0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.anai.2019.08.024","article-title":"Idiopathic anaphylaxis yardstick: practical recommendations for clinical practice","volume":"124","author":"Carter","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.anai.2021.03.008_bib0023","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/1744666X.2017.1334552","article-title":"Anaphylaxis: epidemiology, aetiology and relevance for the clinic","volume":"13","author":"Dhami","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.anai.2021.03.008_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/JAA.S159411","article-title":"Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers","volume":"11","author":"Jimenez-Rodriguez","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"3","key":"10.1016\/j.anai.2021.03.008_bib0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/ACI.0000000000000435","article-title":"Application of precision medicine to the treatment of anaphylaxis","volume":"18","author":"Labella","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2021.03.008_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.00614","article-title":"Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis","volume":"8","author":"Monta\u00f1ez","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2021.03.008_bib0027","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3389\/fimmu.2017.01472","article-title":"Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations","volume":"8","author":"Castells","year":"2017","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.03.008_bib0028","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","article-title":"A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents","volume":"7","author":"Madrigal-Burgaleta","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2021.03.008_bib0029","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaci.2018.10.063","article-title":"Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology","volume":"143","author":"Carter","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2021.03.008_bib0030","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/ijms18061316","article-title":"Drug hypersensitivity and desensitizations: mechanisms and new approaches","volume":"18","author":"de las Vecillas S\u00e1nchez","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.anai.2021.03.008_bib0031","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jaci.2015.10.039","article-title":"Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions","volume":"137","author":"Picard","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.03.008_bib0032","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.alit.2019.04.001","article-title":"Alpha-Gal-containing biologics and anaphylaxis","volume":"68","author":"Chinuki","year":"2019","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.anai.2021.03.008_bib0033","doi-asserted-by":"crossref","first-page":"73","DOI":"10.18176\/jiaci.0046","article-title":"Mechanisms of anaphylaxis beyond IgE","volume":"26","author":"Mu\u00f1oz-Cano","year":"2016","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.03.008_bib0034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaci.2018.09.022","article-title":"Controversies in drug allergy: in vitro testing","volume":"143","author":"Mayorga","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.03.008_bib0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.anai.2020.09.002","article-title":"Challenges in skin testing for progestogen hypersensitivity","volume":"126","author":"Foer","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2021.03.008_bib0036","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jaip.2020.01.047","article-title":"Soluble Fc\u03b5RI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients","volume":"8","author":"Mo\u00f1ino-Romero","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2021.03.008_bib0037","doi-asserted-by":"crossref","unstructured":"Jakubovic BD, Sanchez-Sanchez S, Hamadi S, Lynch D, Castells M. Interleukin-6: a novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association [e-pub ahead of print]. Allergy. doi:10.1111\/all.14644, Accessed October 29, 2020.","DOI":"10.1111\/all.14644"},{"issue":"2","key":"10.1016\/j.anai.2021.03.008_bib0038","doi-asserted-by":"crossref","first-page":"86","DOI":"10.18176\/jiaci.0476","article-title":"Immediate hypersensitivity reactions caused by drug excipients: a literature review","volume":"30","author":"Caballero","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.03.008_bib0039","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11882-015-0515-3","article-title":"Presentation and diagnosis of hypersensitivity to platinum drugs","volume":"15","author":"Caiado","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"10.1016\/j.anai.2021.03.008_bib0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaip.2016.11.006","article-title":"Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy","volume":"5","author":"Giavina-Bianchi","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2021.03.008_bib0041","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11882-019-0852-8","article-title":"BAT in the diagnosis of drug allergy: a novel tool in clinical daily practice?","volume":"19","author":"Campos","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"10.1016\/j.anai.2021.03.008_bib0042","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaip.2015.10.007","article-title":"Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization","volume":"4","author":"Gonz\u00e1lez-de-Olano","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2021.03.008_bib0043","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.jaci.2019.01.010","article-title":"Nanoallergen platform for detection of platin drug allergies","volume":"143","author":"Deak","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.03.008_bib0044","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40521-019-00231-0","article-title":"Update on desensitization","volume":"6","author":"Campos","year":"2019","journal-title":"Curr Treat Options Allergy"},{"issue":"3","key":"10.1016\/j.anai.2021.03.008_bib0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.anai.2020.04.017","article-title":"Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: outcomes and risk factors","volume":"125","author":"Caiado","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.03.008_bib0046","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.anai.2019.03.008","article-title":"Rituximab hypersensitivity and desensitization: a personalized approach to treat cancer and connective tissue diseases","volume":"123","author":"Yang","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2021.03.008_bib0047","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/cea.12520","article-title":"Anaphylaxis and cardiovascular disease: therapeutic dilemmas","volume":"45","author":"Lieberman","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.anai.2021.03.008_bib0048","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaip.2017.04.033","article-title":"Are ACE inhibitors and beta-blockers dangerous in patients at risk for anaphylaxis?","volume":"5","author":"Coop","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2021.03.008_bib0049","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/ACI.0000000000000648","article-title":"Omalizumab and other biologics in drug desensitization","volume":"20","author":"Fernandez","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.03.008_bib0050","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jaip.2017.01.015","article-title":"First case of allergy to nivolumab","volume":"5","author":"S\u00e1enz de Santa Mar\u00eda Garc\u00eda","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2021.03.008_bib0051","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jaip.2020.02.013","article-title":"Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical Platin","volume":"8","author":"Silver","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.anai.2021.03.008_bib0052","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs","volume":"8","author":"Broyles","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.anai.2021.03.008_bib0053","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.jaip.2020.08.005","article-title":"Controversies in allergy: chemotherapy reactions, desensitize, or delabel?","volume":"8","author":"Hong","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2021.03.008_bib0054","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jcph.818","article-title":"Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors","volume":"57","author":"Agrawal","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.anai.2021.03.008_bib0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2500\/aap.2017.38.4085","article-title":"Management of adverse reactions to biologic agents","volume":"38","author":"Isabwe","year":"2017","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"10.1016\/j.anai.2021.03.008_bib0056","first-page":"182","article-title":"Desensitization protocol to nivolumab without corticosteroid use in a kidney cancer patient","volume":"44","author":"Ram\u00edrez-Cruz","year":"2020","journal-title":"Farm Hosp"},{"key":"10.1016\/j.anai.2021.03.008_bib0057","doi-asserted-by":"crossref","unstructured":"Gonzalez-Diaz S, Villarreal-Gonzalez R, De Lira-Quezada C, Rocha-Silva G, Oyervides-Juarez V, Vidal-Gutierrez O. Desensitization protocol to atezolizumab and bevacizumab after severe anaphylaxis in the treatment of lung adenocarcinoma [e-pub ahead of print]. J Investig Allergol Clin Immunol. doi:10.18176\/jiaci.0637, Accessed August 26, 2020.","DOI":"10.18176\/jiaci.0637"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062100185X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062100185X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:25:50Z","timestamp":1761053150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112062100185X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S108112062100185X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2021.03.008","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor\u2013monoclonal antibodies and desensitization","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}